# The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)

> **NCT01160640** · PHASE2 · COMPLETED · sponsor: **Harold Wiesenfeld** · enrollment: 233 (actual)

## Conditions studied

- Pelvic Inflammatory Disease

## Interventions

- **DRUG:** Ceftriaxone
- **DRUG:** Doxycycline
- **DRUG:** Metronidazole
- **DRUG:** Placebo Oral Capsule

## Key facts

- **NCT ID:** NCT01160640
- **Lead sponsor:** Harold Wiesenfeld
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2018-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01160640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01160640, "The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01160640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*